CAUTIONFEDGLP-1 Compounding2025-11-24
FDA / Federal Register Notice: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
FDA seeks comments on human drug compounding practices.
What to do
Free
Enter your email to unlock “What to do” on every alert — and get the weekly Brief. No charge.
Want it filtered to YOUR states + real-time alerts? Become a member →
Federal Register · primary source ↗
Related alerts
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
- FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
- FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
Monitoring, not legal advice.